Catalyst Oncology

Actavis’ generic breast cancer drug, Epirubicin Hydrochloride Injection, has been approved for sale in the US by the Food & Drug Administration (FDA). Epirubicin Hydrochloride is now the second oncology drug from Actavis approved in the US following Irinotecan Hydrochloride which was authorised earlier this year. Epirubicin Hydrochloride Injection, the generic to Pfizer’s Ellence®, has been approved in 10 mg / 5 mL, 50 mg / 25 mL, and 200 mg / 100 mL configurations and is indicated as a

See the original post here:
Actavis receives US approval for generic breast cancer drug